Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902269 | 0.89 | RAB9A (0.69) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3473707 | 0.82 | KMT2A (0.53) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3472182 | 0.80 | RAB9A (0.36) | RAB9ANPC1KDM4EHSD17B10CASP1 | |
| SCHEMBL24238258 | 0.78 | HPGD (0.51) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL21995498 | 0.78 | MEN1 (0.55) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1901480 | 0.75 | RAB9A (1.00) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29820118 | 0.75 | RAB9A (1.00) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1782708 | 0.74 | PARP1 (0.43) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24238263 | 0.74 | KDM4E (0.43) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1976588 | 0.74 | RAB9A (0.47) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | CERUS CORP (US) | 2026-02-05 | — | — | US | claimed |
| US-12364949-B2 | Method for electrochemical gas separation | VERDOX, INC. (US) | 2025-07-22 | — | — | US | claimed |
| US-12365850-B2 | Water-miscible functional fluid, undiluted stock of water-miscible functional fluid, sterilizer for water-miscible functional fluid, and method of sterilizing water-miscible function fluid | YUSHIRO CHEMICAL INDUSTRY CO., LTD. (JP) | 2025-07-22 | — | — | US | claimed |
| EP-3934594-B1 | ENERGY AUGMENTATION STRUCTURES FOR USE IN NON-INVASIVE IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT LLC (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250144562-A1 | ELECTROCHEMICAL CO2 CAPTURE WITH AIR STABLE REDOX SPECIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2025-05-08 | — | — | US | claimed |
| EP-4255626-B1 | HETEROGENEOUS REDOX CATALYTIC SYSTEM | ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOMATERIALES CIC BIOMAGUNE (ES) | 2025-02-12 | — | — | EP | claimed |
| WO-2025019426-A1 | ELECTROCHEMICAL CO2 CAPTURE WITH AIR STABLE REDOX SPECIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-23 | — | — | WO | claimed |
| EP-3367890-B1 | A PHOTOACTIVATABLE DRUG FOR USE IN RADIOTHERAPY | IMMUNOLIGHT LLC (US) | 2024-12-04 | — | — | EP | claimed |
| CN-118994174-A | Isoalloxazine compound, preparation method and application thereof in preparation of flexible non-binder zinc ion battery anode material | 厦门大学 | 2024-11-22 | — | — | CN | claimed |
| US-12121746-B2 | Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in methods and systems for treating cell proliferation disorders | IMMUNOLIGHT, LLC (US) | 2024-10-22 | — | — | US | claimed |
| EP-0390132-A2 | Electronic device | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1990-10-03 | — | — | EP | claimed |
| EP-0384366-A2 | Photosensitive recording element | BASF Aktiengesellschaft (DE) | 1990-08-29 | — | — | EP | claimed |
| US-4654378-A | Process for the manufacture of high solids, free-flowing, granular poly(dimethyldiallyl ammonium chloride) | CALGON CORPORATION (US) | 1987-03-31 | — | — | US | claimed |
| US-4629696-A | USING NADPH, A DIAPHORASE AND A REDOX PARTNER TO PRODUCE SUPEROXIDE, HYDROGEN PEROXIDE OR HYDROXYL RADICALS; QUANTITATIVE ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-12-16 | — | — | US | claimed |
| EP-0105443-B1 | METHOD OF SELECTIVELY PRODUCING REDUCED OXYGEN SPECIES AND REAGENTS SUITABLE THEREFOR | Roche Diagnostics GmbH (DE) | 1986-07-02 | — | — | EP | claimed |
| EP-0105443-A2 | Method of selectively producing reduced oxygen species and reagents suitable therefor | Roche Diagnostics GmbH (DE) | 1984-04-18 | — | — | EP | claimed |
| EP-0030550-A1 | ANTIHYPERTENSIVE AGENTS AND THEIR USE IN TREATMENT OF HYPERTENSION | TRACHEWSKY, Daniel (US) | 1981-06-24 | — | — | EP | claimed |
| US-4264601-A | SUBSTITUTED ISOALLOXAZINES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1981-04-28 | — | — | US | claimed |
| WO-1980002799-A1 | ANTIHYPERTENSIVE AGENTS AND THEIR USE IN TREATMENT OF HYPERTENSION | TRACHEWSKY D | 1980-12-24 | — | — | WO | claimed |
| US-4111692-A | ALIPHATIC NITROGEN COMPOUND, HALOGEN COMPOUND AS FREE RADICAL GENERATOR | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1978-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | PRF1, CFD, F5 | RAB9A 3475/4885NPC1 1276/4885KDM4E 4393/4885 |
| US-12121746-B2 | Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in methods and systems for treating cell proliferation disorders | TK2, GFM1, HDGF | RAB9A 4376/4885NPC1 1080/4885KDM4E 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.